Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential hypofractionated radiotherapy followed by atezolizumab in recurrent or refractory small cell lung cancer
KCT0005443Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in small cell lung cancer (SCLC), sponsored by Roche. Started Nov 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on KCT0005443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005443.